What NICE guidance on weight loss injections actually says

What the NICE appraisals actually concluded

The most useful starting point is the published guidance itself, not a summary of a summary. You can read a detailed breakdown of what the appraisals mean for patients in our guide to the NICE guidelines on weight loss injections. NICE's appraisal of tirzepatide (TA1026, published 23 December 2024, updated 1 September 2025) recommends it for adults with a BMI of 35 or above and at least one weight-related comorbidity — conditions such as high blood pressure, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI threshold is reduced by 2.5 kg/m², reflecting established differences in health risk at lower body weights. NICE also states that if a patient achieves less than 5% weight loss after six months at the highest tolerated dose, continuing treatment should be reviewed. That stopping rule matters: it means ongoing access is conditional on demonstrable progress, not open-ended.

The NICE appraisal of semaglutide (TA875, published 8 March 2023) recommends Wegovy for adults with a BMI of 35 or above and at least one weight-related condition, but with an important structural requirement: it must be used within a specialist weight management service providing multidisciplinary support, and for a maximum of two years. The ethnic-background BMI adjustment applies here too. NHS England quotes adjusted thresholds of 32.5 instead of 35, and 27.5 to 32.4 instead of 30 to 34.9, for the relevant backgrounds. You can read both appraisals in full on the NICE website.

The clinical evidence that underpinned the decisions

NICE appraisals are only as strong as the trials behind them. For tirzepatide, the pivotal SURMOUNT-1 study (published in the New England Journal of Medicine) randomised 2,539 adults with obesity over 72 weeks. Participants taking the 15 mg dose lost around 20 to 21% of body weight on average. The SURMOUNT-5 head-to-head trial, also published in the NEJM in 2025, compared tirzepatide directly with semaglutide 2.4 mg and found greater average weight reduction with tirzepatide, a finding the NICE committee factored into its indirect comparisons. For semaglutide, the STEP 1 trial (68 weeks, also published in the NEJM) found average weight loss of around 15% at the 2.4 mg maintenance dose. It is worth being clear about one common misconception here: these figures are trial averages, not individual predictions. Your own response depends on biology, adherence and the lifestyle changes you make alongside treatment. A prescriber can help you set realistic expectations rather than benchmark yourself against a headline number.

If you want to explore the broader landscape of available treatments before looking at specific guidance, the weight loss injections overview covers both licensed options in plain terms.

How NHS access is being phased in, and where that leaves you

NICE recommendations don't automatically mean immediate NHS availability. NHS England is implementing tirzepatide access in stages, tied to BMI and the number of qualifying comorbidities a person holds. The first cohort (adults with a BMI of 40 or above and four or more of the five listed conditions) became eligible from June 2025. A second cohort covering BMI 35 to 39.9 with four or more conditions was activated on 23 June 2026. From around March 2027, the criteria are expected to widen further. Even then, participation by GP practices is not universal: from 1 April 2026, practices may prescribe under the new GP contract, but only where they have opted in. The NHS England weight management injections page sets out the current requirements clearly.

For Wegovy on the NHS, access typically runs through specialist weight management services, where waiting lists are commonly long. People in Northern Ireland and other devolved nations may find that local thresholds and pathways differ from those in England. The practical upshot is that NICE guidance and NHS eligibility are not the same thing: meeting the clinical criteria does not guarantee an NHS prescription, and the waiting time before one becomes available varies widely by area. That gap is why many people explore a regulated private route. Private treatment through a GPhC-registered pharmacy still requires clinical assessment (the prescription is not optional) but there is no referral, no waiting list and no requirement to be enrolled in a specialist service. If you are considering this route, our guide to weight loss injections insurance explains how coverage works and what to check before you commit. For context on what private treatment typically costs, our guide to weight loss injections finance covers how pricing is structured and what a legitimate quote should include.

What NICE guidance does not cover, and who fills the gap

NICE appraisals address NHS commissioning. They do not regulate private prescribing, set private prices, or restrict a licensed medicine to NHS use only. A GPhC-registered prescriber working in a private pharmacy can legally prescribe Mounjaro or Wegovy for any patient who meets the licensed eligibility criteria in the SmPC, BMI 30 or above, or 27 or above with a qualifying weight-related condition. Those private thresholds are broader than the NHS ones. That distinction sometimes surprises people who have been told they don't qualify, when what they were really told is that they don't qualify under the NHS criteria at this point in the rollout. The licensed criteria and the NHS criteria are different documents serving different purposes.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reading your responses, not automated decision software. If you order by 12pm on a working day and your treatment is clinically approved, it is dispatched the same day and delivered free the next working day by DPD, in plain packaging. Patients based in Idaho can find region-specific information on our weight loss injections Boise page, which covers local access and how to get started. If you have questions before starting, the FAQs page covers common queries, and the weight loss treatment overview explains the full range of options we offer. Ready to find out whether you're clinically suitable? Start your free consultation and a prescriber will review your case the same day.